---
title: "Sanofi, UCB, Opella join ERM-Secaro Clean Heat Program to cut supply chain emissions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299179273.md"
description: "ERM launched the Clean Heat Program with Secaro to decarbonize industrial heat in pharmaceutical supply chains. Sanofi, UCB, and Opella joined AstraZeneca as founding members to replace fossil fuels with low-carbon alternatives. The initiative addresses supplier barriers like funding and expertise, targeting healthcare's significant emission contribution. Partners include Schneider Electric and 3Degrees for audits and energy management."
datetime: "2026-09-16T12:01:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299179273.md)
  - [en](https://longbridge.com/en/news/299179273.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299179273.md)
generator: "portal-rs"
---

# Sanofi, UCB, Opella join ERM-Secaro Clean Heat Program to cut supply chain emissions

-   ERM launched a Clean Heat Program with Secaro to accelerate industrial heat decarbonization across pharmaceutical supply chains. \* Sanofi, UCB, Opella joined AstraZeneca as founding members, aiming to replace fossil fuel-based heating with low-carbon alternatives. \* Program targets key barriers for suppliers, including limited expertise, weak engagement, funding constraints, and complex heat-system upgrades. \* ERM cited healthcare at about 5% of global emissions, framing supply-chain heat as a major remaining operational decarbonization lever. \* Secaro expanded the program’s partner network with Schneider Electric and 3Degrees to support supplier audits, energy management, and biomethane procurement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ERM Group Inc. published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [UCB.US](https://longbridge.com/en/quote/UCB.US.md)
- [SBGSY.US](https://longbridge.com/en/quote/SBGSY.US.md)
- [UCBJY.US](https://longbridge.com/en/quote/UCBJY.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective](https://longbridge.com/en/news/298875452.md)
- [Key facts: AstraZeneca (AZN) NICE OK Enhertu; FDA review; China plan](https://longbridge.com/en/news/299411391.md)
- [Cheplapharm to take over 20 medicines and three sites from Sanofi](https://longbridge.com/en/news/299028828.md)
- [AstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,500](https://longbridge.com/en/news/298918563.md)
- [AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears](https://longbridge.com/en/news/298828016.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**